DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.56%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$362M
AUM Growth
+$362M
(+2.7%)
Cap. Flow
-$9.38M
Cap. Flow
% of AUM
-2.59%
Top 10 Holdings %
Top 10 Hldgs %
55.78%
Holding
86
New
3
Increased
22
Reduced
21
Closed
10
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$2.11M |
| 2 |
Compass Therapeutics
CMPX
|
$1.37M |
| 3 |
Inogen
INGN
|
$1.04M |
| 4 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$975K |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$961K |
Top Sells
| 1 |
Merus
MRUS
|
$3.31M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$3.05M |
| 3 |
TSVT
2seventy bio
TSVT
|
$2.12M |
| 4 |
UroGen Pharma
URGN
|
$1.96M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$1.93M |
Sector Composition
| 1 | Healthcare | 85.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
ProQR Therapeutics
PRQR
$241M
| $3.2M | 0.88% |
1,567,561
| – | – |
|
27
Edgewise Therapeutics
EWTX
$1.57B
| $3.12M | 0.86% |
238,140
+55,000
| +30% | +$721K |
|
28
Insulet
PODD
$24.3B
| $3.11M | 0.86% |
9,900
-2,000
| -17% | -$628K |
|
29
Immunovant
IMVT
$2.63B
| $3.06M | 0.85% |
191,493
+21,497
| +13% | +$344K |
|
30
Alkermes
ALKS
$4.85B
| $2.97M | 0.82% |
103,748
+9,548
| +10% | +$273K |
|
|
BCAX
31
Bicara Therapeutics Inc. Common Stock
BCAX
$649M
| $2.94M | 0.81% |
317,001
+105,000
| +50% | +$975K |
|
32
TELA Bio
TELA
$68.9M
| $2.8M | 0.77% |
1,441,029
| – | – |
|
33
Kura Oncology
KURA
$690M
| $2.67M | 0.74% |
463,368
| – | – |
|
34
Denali Therapeutics
DNLI
$2.26B
| $2.36M | 0.65% |
168,500
+40,600
| +32% | +$568K |
|
|
CMPS
35
Compass Pathways
CMPS
$434M
| $2.27M | 0.63% |
811,046
+100,000
| +14% | +$280K |
|
36
Align Technology
ALGN
$9.94B
| $2.08M | 0.57% |
11,000
| – | – |
|
|
37
BioCryst Pharmaceuticals
BCRX
$1.74B
| $1.96M | 0.54% |
218,255
-340,000
| -61% | -$3.05M |
|
38
Astria Therapeutics
ATXS
$372M
| $1.74M | 0.48% |
324,775
+10,000
| +3% | +$53.6K |
|
39
Keros Therapeutics
KROS
$638M
| $1.74M | 0.48% |
130,316
| – | – |
|
40
Viking Therapeutics
VKTX
$3.09B
| $1.71M | 0.47% |
64,516
| – | – |
|
41
Accuray
ARAY
$153M
| $1.67M | 0.46% |
1,222,358
| – | – |
|
|
BWAY
42
Brainsway
BWAY
$288M
| $1.67M | 0.46% |
127,151
-29,382
| -19% | -$386K |
|
43
Allogene Therapeutics
ALLO
$249M
| $1.56M | 0.43% |
1,380,118
| – | – |
|
44
Lexeo Therapeutics
LXEO
$259M
| $1.52M | 0.42% |
378,083
| – | – |
|
45
Foghorn Therapeutics
FHTX
$298M
| $1.41M | 0.39% |
300,452
-4,300
| -1% | -$20.2K |
|
46
iTeos Therapeutics
ITOS
| $1.4M | 0.39% |
140,847
-72,500
| -34% | -$723K |
|
47
Oric Pharmaceuticals
ORIC
$1.01B
| $1.37M | 0.38% |
135,271
-106,729
| -44% | -$1.08M |
|
|
48
Compass Therapeutics
CMPX
$474M
| $1.37M | 0.38% |
+526,660
| New | +$1.37M |
|
49
Immatics
IMTX
$649M
| $1.32M | 0.36% |
245,000
| – | – |
|
50
Alector
ALEC
$262M
| $1.28M | 0.35% |
912,928
| – | – |
|